Table 1
Number of patients by type of treatment, breakdown of patients by age, and monthly drug costs
| Treatment | Age, <75 yr | Age, ≥75 yr | Total | Cost per month, JPY | |
|---|---|---|---|---|---|
| ADT alone | 36 (9.6%) | 60 (18.5%) | 96 (13.7%) | 16 383 | |
| ADT+ antiandrogen | 87 (23.2%) | 94 (28.9%) | 181 (25.9%) | 21 319 | |
| ADT+ docetaxel | 19 (5.1%) | 9 (2.8%) | 28 (4.0%) | 54 693 | |
| ADT+ abiraterone | 76 (20.3%) | 71 (21.8%) | 147 (21.0%) |  | 424 746 |
| ADT+ apalutamide | 69 (18.4%) | 32 (9.8%) | 101 (14.4%) | 272 874 | |
| ADT+ enzalutamide | 88 (23.5%) | 59 (18.2%) | 147 (21.0%) | 275 971 | |
| Total | 375 (100%) | 325 (100%) | 700 (100%) |
| Treatment | Age, <75 yr | Age, ≥75 yr | Total | Cost per month, JPY | |
|---|---|---|---|---|---|
| ADT alone | 36 (9.6%) | 60 (18.5%) | 96 (13.7%) | 16 383 | |
| ADT+ antiandrogen | 87 (23.2%) | 94 (28.9%) | 181 (25.9%) | 21 319 | |
| ADT+ docetaxel | 19 (5.1%) | 9 (2.8%) | 28 (4.0%) | 54 693 | |
| ADT+ abiraterone | 76 (20.3%) | 71 (21.8%) | 147 (21.0%) | | 424 746 |
| ADT+ apalutamide | 69 (18.4%) | 32 (9.8%) | 101 (14.4%) | 272 874 | |
| ADT+ enzalutamide | 88 (23.5%) | 59 (18.2%) | 147 (21.0%) | 275 971 | |
| Total | 375 (100%) | 325 (100%) | 700 (100%) |
ADT, androgen deprivation therapy.
Table 1
Number of patients by type of treatment, breakdown of patients by age, and monthly drug costs
| Treatment | Age, <75 yr | Age, ≥75 yr | Total | Cost per month, JPY | |
|---|---|---|---|---|---|
| ADT alone | 36 (9.6%) | 60 (18.5%) | 96 (13.7%) | 16 383 | |
| ADT+ antiandrogen | 87 (23.2%) | 94 (28.9%) | 181 (25.9%) | 21 319 | |
| ADT+ docetaxel | 19 (5.1%) | 9 (2.8%) | 28 (4.0%) | 54 693 | |
| ADT+ abiraterone | 76 (20.3%) | 71 (21.8%) | 147 (21.0%) | | 424 746 |
| ADT+ apalutamide | 69 (18.4%) | 32 (9.8%) | 101 (14.4%) | 272 874 | |
| ADT+ enzalutamide | 88 (23.5%) | 59 (18.2%) | 147 (21.0%) | 275 971 | |
| Total | 375 (100%) | 325 (100%) | 700 (100%) |
| Treatment | Age, <75 yr | Age, ≥75 yr | Total | Cost per month, JPY | |
|---|---|---|---|---|---|
| ADT alone | 36 (9.6%) | 60 (18.5%) | 96 (13.7%) | 16 383 | |
| ADT+ antiandrogen | 87 (23.2%) | 94 (28.9%) | 181 (25.9%) | 21 319 | |
| ADT+ docetaxel | 19 (5.1%) | 9 (2.8%) | 28 (4.0%) | 54 693 | |
| ADT+ abiraterone | 76 (20.3%) | 71 (21.8%) | 147 (21.0%) | | 424 746 |
| ADT+ apalutamide | 69 (18.4%) | 32 (9.8%) | 101 (14.4%) | 272 874 | |
| ADT+ enzalutamide | 88 (23.5%) | 59 (18.2%) | 147 (21.0%) | 275 971 | |
| Total | 375 (100%) | 325 (100%) | 700 (100%) |
ADT, androgen deprivation therapy.
